Compare Amylx Pharmaceuticals Inc (AMLX) vs Cardinal Health Inc (CAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Cardinal Health Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Cardinal Health Inc trades at $236.48 (market cap $55.23B). The key difference: Cardinal Health Inc is far larger — about 27.9× Amylx Pharmaceuticals Inc's market cap, and Cardinal Health Inc pays a 0.87% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CAH | |
|---|---|---|
Market Cap | $1.98B | $55.23B |
Sector | Health | Health |
52-Week High | $18.70 | $239.71 |
52-Week Low | $7.64 | $146.04 |
Enterprise Value | $1.70B | $60.20B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Cardinal Health (CAH) trades at $235.80, up 0.87% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 37.08% ROE and positive revenue growth trends from $222.58B in 2025 to projected $250.7B in 2026. Recent removal from Russell indices has not dampened analyst optimism, with 54.55% maintaining buy ratings and a $248 consensus price target representing 5% upside potential.
The outlook remains positive given CAH's defensive healthcare distribution business and specialty pharma expansion. Key risks include negative shareholder equity of -$3.21B and elevated debt levels with 16.09% debt-to-asset ratio. Earnings momentum from three consecutive quarterly beats supports the bullish case, though investors should monitor the upcoming Q2 2026 results against $2.41 EPS expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
